This product belongs to the macrolide antibiotics. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), all groups of streptococci and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Legionella, Campylobacter fetus, certain spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on certain bacteria at high concentrations. It can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site ("P" site), blocking the transfer RNA (t-RNA) from binding to the "P" site, and also blocking the self-acceptor site ("A" site) of the polypeptide chain.

This product has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase. It stops the formation of pain nerve impulses in inflammatory tissues and inhibits inflammatory reactions, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. As for the antipyretic effect, it acts on the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating, which increases heat dissipation. This central antipyretic effect may also be related to the inhibition of prostaglandin synthesis in the hypothalamus.

Replenishing Qi, dispelling wind, opening the orifices

Replenishing Qi, dispelling wind, opening the orifices

Replenishing Qi, dispelling wind, opening the orifices

Replenishing Qi, dispelling wind, opening the orifices

Replenishing Qi, dispelling wind, opening the orifices

Replenishing Qi, dispelling wind, opening the orifices

Replenishing Qi, dispelling wind, opening the orifices

This product is a chemical synthesis of isoniazid (INH) and para-aminosalicylic acid (PAS). INH is mainly effective against mycobacteria in the growth and reproduction period, and may inhibit the synthesis of mycolic acid (myolic acid) of sensitive bacteria and cause cell wall rupture. PAS effectively delays and blocks the acetylation process of INH in the body, so this product maintains a higher and longer INH concentration in the blood and reduces liver toxicity. Clinically confirmed, in combination with other anti-tuberculosis drugs, the anti-tuberculosis efficacy of this product is significantly better than INH, while the incidence of gastrointestinal reactions, liver damage and leukopenia, and adverse reactions is significantly lower than INH. Animal experiments show that for artificially infected mice, the anti-tuberculosis efficacy of this product is about 5 times that of INH.

This product is a chemical synthesis of isoniazid (INH) and para-aminosalicylic acid (PAS). INH is mainly effective against mycobacteria in the growth and reproduction period, and may inhibit the synthesis of mycolic acid (myolic acid) of sensitive bacteria and cause cell wall rupture. PAS delays and blocks the acetylation process of INH in the body, enhances the bactericidal effect of the drug and delays the development of bacterial resistance. Clinically confirmed, in combination with other anti-tuberculosis drugs, the anti-tuberculosis efficacy of this product is significantly better than INH, and the incidence of adverse reactions is significantly lower than INH. Animal experiments show that the anti-tuberculosis efficacy of this product is about 5 times that of INH.